Delivery Order SPE2DB24D2109-SPE2DB26FHVTQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $11,089.97. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dapagliflozin 5 mg tablets in 30-count packages, with a ceiling value of $1,401.85 and an ultimate completion date of October 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,971.96. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The order is scheduled for ultimate completion on August 27, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets, with a ceiling value of $67,208.92. This non-set-aside, competitively awarded contract employs firm fixed pricing and maintains an ultimate completion date of August 18, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,492.03 and an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dapagliflozin is a diabetes...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $6,100.21 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The order was placed to the company's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package. This order is valued at $1,825.56 with a firm fixed price structure and carries a completion date of July 30, 2025. The contract involves no set-aside designation, indicating it was competitively awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $4,022.60. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is expected to reach completion by September 9, 2025. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count) with a contract value of $1,224.06 and a completion date of October 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB26FHVTQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This is a firm fixed price delivery order valued at $69,665.43 with an ultimate completion date of October 23, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Dapagliflozin is a diabetes medication commonly used within the Department of Defense healthcare system, and this order reflects the company's established role as a primary pharmaceutical vendor for military medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $69.7k | 10/22/25 |